These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

181 related items for PubMed ID: 19648168

  • 21. Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia.
    Hochhaus A, Larson RA, Guilhot F, Radich JP, Branford S, Hughes TP, Baccarani M, Deininger MW, Cervantes F, Fujihara S, Ortmann CE, Menssen HD, Kantarjian H, O'Brien SG, Druker BJ, IRIS Investigators.
    N Engl J Med; 2017 Mar 09; 376(10):917-927. PubMed ID: 28273028
    [Abstract] [Full Text] [Related]

  • 22. Efficacy and safety of imatinib in patients with chronic myeloid leukemia and complete or near-complete cytogenetic response to interferon-alpha.
    Branford S, Hughes T, Milner A, Koelmeyer R, Schwarer A, Arthur C, Filshie R, Moreton S, Lynch K, Taylor K.
    Cancer; 2007 Aug 15; 110(4):801-8. PubMed ID: 17607681
    [Abstract] [Full Text] [Related]

  • 23. [Imatinib combination therapies--the new CML Study 4].
    Helmann R, Berger U, Engelich G.
    Dtsch Med Wochenschr; 2002 Oct 18; 127(42):224-6. PubMed ID: 12430568
    [No Abstract] [Full Text] [Related]

  • 24. U.S. Food and Drug Administration Drug Approval Summary: conversion of imatinib mesylate (STI571; Gleevec) tablets from accelerated approval to full approval.
    Cohen MH, Johnson JR, Pazdur R.
    Clin Cancer Res; 2005 Jan 01; 11(1):12-9. PubMed ID: 15671523
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.
    Hochhaus A, O'Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Müller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA, IRIS Investigators.
    Leukemia; 2009 Jun 01; 23(6):1054-61. PubMed ID: 19282833
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. A pilot study of imatinib, low-dose cytarabine and idarubicin for patients with chronic myeloid leukemia in myeloid blast phase.
    Quintás-Cardama A, Kantarjian H, Garcia-Manero G, O'Brien S, Faderl S, Ravandi F, Giles F, Thomas D, Wierda W, Cortes J.
    Leuk Lymphoma; 2007 Feb 01; 48(2):283-9. PubMed ID: 17325887
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Efficacy of escalated imatinib combined with cytarabine in newly diagnosed patients with chronic myeloid leukemia.
    Deenik W, Janssen JJ, van der Holt B, Verhoef GE, Smit WM, Kersten MJ, Daenen SM, Verdonck LF, Ferrant A, Schattenberg AV, Sonneveld P, van Marwijk Kooy M, Wittebol S, Willemze R, Wijermans PW, Beverloo HB, Löwenberg B, Valk PJ, Ossenkoppele GJ, Cornelissen JJ.
    Haematologica; 2010 Jun 01; 95(6):914-21. PubMed ID: 20015886
    [Abstract] [Full Text] [Related]

  • 31. Treatment of Philadelphia chromosome-positive early chronic phase chronic myelogenous leukemia with daily doses of interferon alpha and low-dose cytarabine.
    Kantarjian HM, O'Brien S, Smith TL, Rios MB, Cortes J, Beran M, Koller C, Giles FJ, Andreeff M, Kornblau S, Giralt S, Keating MJ, Talpaz M.
    J Clin Oncol; 1999 Jan 01; 17(1):284-92. PubMed ID: 10458244
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. [Tyrosine kinase inhibitors for the treatment of CML].
    Heim D.
    Ther Umsch; 2006 Apr 01; 63(4):249-54. PubMed ID: 16689455
    [Abstract] [Full Text] [Related]

  • 34. Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS).
    Hughes TP, Hochhaus A, Branford S, Müller MC, Kaeda JS, Foroni L, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Rudoltz MS, Mone M, Wehrle E, Modur V, Goldman JM, Radich JP, IRIS investigators.
    Blood; 2010 Nov 11; 116(19):3758-65. PubMed ID: 20679528
    [Abstract] [Full Text] [Related]

  • 35. In vitro effects of STI 571-containing drug combinations on the growth of Philadelphia-positive chronic myelogenous leukemia cells.
    Scappini B, Onida F, Kantarjian HM, Dong L, Verstovsek S, Keating MJ, Beran M.
    Cancer; 2002 May 15; 94(10):2653-62. PubMed ID: 12173333
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Imatinib combined with mitoxantrone/etoposide and cytarabine is an effective induction therapy for patients with chronic myeloid leukemia in myeloid blast crisis.
    Fruehauf S, Topaly J, Buss EC, Fischer T, Ottmann OG, Emmerich B, Müller MC, Schuld P, Balleisen L, Hehlmann R, Ho AD, Hochhaus A.
    Cancer; 2007 Apr 15; 109(8):1543-9. PubMed ID: 17340589
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Quality of life in patients with newly diagnosed chronic phase chronic myeloid leukemia on imatinib versus interferon alfa plus low-dose cytarabine: results from the IRIS Study.
    Hahn EA, Glendenning GA, Sorensen MV, Hudgens SA, Druker BJ, Guilhot F, Larson RA, O'Brien SG, Dobrez DG, Hensley ML, Cella D, IRIS Investigators.
    J Clin Oncol; 2003 Jun 01; 21(11):2138-46. PubMed ID: 12775739
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.